Workflow
Foreign Currency Risk
icon
Search documents
Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now?
ZACKSยท 2025-07-09 13:26
Core Insights - Thermo Fisher Scientific Inc. (TMO) is focused on growth through strategic acquisitions and product launches, while facing challenges from macroeconomic volatility and foreign currency exchange [1][9][10] Financial Performance - TMO's stock has increased by 20.6% over the past year, outperforming the industry which declined by 11.3% and the S&P 500 which gained 10.2% [2] - The company has a market capitalization of $158.1 billion and an earnings yield of 5.3%, significantly higher than the industry's -2.8% [2] - TMO has consistently surpassed earnings estimates over the past four quarters, with an average surprise of 2.3% [2] Growth Strategies - A notable acquisition includes Solventum's Purification & Filtration business for $4.1 billion, expected to enhance TMO's biologics capabilities and deliver $125 million in adjusted operating income synergies over five years [3][7] - The acquisition of Olink has strengthened TMO's position in the high-growth proteomics market [3][7] - Recent product launches include the CorEvitas Adolescent Alopecia Areata Registry and the Invitrogen EVOS S1000 Spatial Imaging System, aimed at addressing specific market needs [4][7] Research and Development - TMO is increasing its R&D investments, with a projected 51.1% rise in R&D expenses for the second quarter of 2025 [5] Financial Health - As of March 29, 2025, TMO has a long-term debt of $31.37 billion, with cash and cash equivalents totaling $5.95 billion, indicating strong liquidity [8] - The times interest earned ratio stands at 6.3%, reflecting stable solvency [8] Macroeconomic Challenges - TMO is facing macroeconomic challenges, including geopolitical tensions and supply chain disruptions, which may impact profitability [9] - The company has experienced a 1% unfavorable effect on revenues in Q1 2025 due to currency translation from a stronger U.S. dollar [10] Earnings Estimates - The Zacks Consensus Estimate for TMO's earnings per share (EPS) has increased to $22.34, with 2025 revenue estimates at $43.71 billion, indicating a 1.9% rise from the previous year [11]